Gemma Salvadó, PhD, Lund University, Lund, Sweden, comments on the potential of plasma ptau217 as a biomarker for selecting participants who are cognitively unimpaired to be included in Alzheimer’s disease (AD) prevention trials. Dr Salvadó highlights that plasma ptau217 can be used as a screening tool for this population and is especially effective when combined with cerebrospinal fluid (CSF) or positron emission tomography (PET) biomarkers. This approach can help reduce the number of invasive tests, the burden to individuals, and the cost of clinical trials, making it a promising method for clinical trial inclusion selection. This interview took place at the Alzheimer’s Association International Conference® (AAIC) 2024 in Philadelphia, PA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
